Duration of HIV-1 Viral Suppression on Cessation of Antiretroviral Therapy in Primary Infection Correlates with Time on Therapy

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Stöhr, Wolfgang ^a   Fidler, Sarah ^b   McClure, Myra ^b   Weber, Jonathan ^b   Cooper, David ^c   Ramjee, Gita ^d   Kaleebu, Pontiano ^e   Tambussi, Giuseppe ^f   Schechter, Mauro ^g   Babiker, Abdel ^a   Phillips, Rodney E ^h,i   Porter, Kholoud ^a   Frater, John ^h,i  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d HIV Prevention Research Unit   (South Africa)

^e UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^f SAN RAFFAELE HOSPITAL   (Italy)

^g FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ and University of Bristol   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CONTROL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ONSET AGE; OUTCOME ASSESSMENT; PRIMARY INFECTION; RANDOMIZED CONTROLLED TRIAL; REBOUND; SEROCONVERSION; SEX DIFFERENCE; TREATMENT DURATION; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; KAPLAN MEIER METHOD; PROCEDURES; PROPORTIONAL HAZARDS MODEL; VIROLOGY; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; RNA, VIRAL; VIRAL LOAD; YOUNG ADULT;

EID: 84886401909     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078287     Document Type: Article

References (15)

1. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, et al. (1995) In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1: 1284-1290. doi:10.1038/nm1295-1284. PubMed: 7489410.
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300. doi:10.1126/science.278.5341.1295. PubMed: 9360927.
3. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, et al. (2010) Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 24: 1598-1601. doi:10.1097/QAD.0b013e32833b61ba. PubMed: 20549847.
4. Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, et al. (2012) Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med 172: 1252-1255. doi:10.1001/archinternmed.2012.2719. PubMed: 22826124.
5. Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, et al. (2012) HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther (Lond) 17: 1001-1009. doi:10.3851/IMP2273. PubMed: 22865544.
6. Fidler S, Porter K, Ewings F, Frater J, Ramjee G, et al. (2013) Short-Course Antiretroviral Therapy in Primary HIV Infection. N Engl J Med 368: 207-217. doi:10.1056/NEJMoa1110039. PubMed: 23323897.
7. Goujard C, Chaix M-L, Lambotte O, Deveau C, Sinet M, et al. (2009) Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis 49: 982-986. doi:10.1086/605504. PubMed: 19681706.
8. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, et al. (2000) Immune control of HIV-1 after early treatment of acute infection. Nature 407: 523-526. doi:10.1038/35035103. PubMed: 11029005.
9. Lyles RH, Muñoz A, Yamashita TE, Bazmi H, Detels R, et al. (2000) Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 181: 872-880. doi:10.1086/315339. PubMed: 10720507.
10. Madec Y, Boufassa F, Porter K, Meyer L, CASCADE Collaboration (2005) Spontaneous control of viral load and CD4 cell count progression among HIV-1 seroconverters. AIDS 19: 2001-2007. doi:10.1097/01.aids.0000194134.28135.cd. PubMed: 16260907.
11. Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, et al. (n.d.) Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLOS Pathog 9: e1003211. PubMed: 23516360.
12. Grijsen ML, Steingrover R, Wit FWNM, Jurriaans S, Verbon A, et al. (2012) No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLOS Med 9: e1001196. PubMed: 22479156.
13. Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, et al. (2012) Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PLOS ONE 7: e32369. doi:10.1371/journal.pone.0032369. PubMed: 22412867.
14. Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix M-L, et al. (2013) Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clin Infect Dis 56: 888-897. doi:10.1093/cid/cis1000. PubMed: 23223594.
15. Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, et al. (2010) Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy. J International AIDS Society 13: 4. 1758-2652-13-4 PubMed: 20205896.